tbuckley/cabot-search huggingface dataset:
Diabetes Complications—Can They Be Reversed?
Authors: E CONSTANTINOU
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
OC-115 The use of sofosbuvir based regimens amongst treatment naive and experienced patients with advanced fibrosis/cirrhosis: real world results from a difficult to treat cohort
Authors: D Sutherland, E Forrest, M Heydtmann, M Priest, PR Mills, J Morris, A Stanley, R Fox, S Barclay
Journal: Gut (2015)

<h3>Introduction</h3> Patients with cirrhosis account for 17–23% of subjects in Phase 3 trials of Sofosbuvir, however strict inclusion/exclusion criteria may make outcomes less reproducible in routine practice. Data is lacking for GT1 treatment experienced (TE) patients, and data for treating GT3 patients with interferon based regimens limited. We sought to establish the tolerability and effectiveness of Sofosbuvir based regimens in such patients with advanced fibrosis/cirrhosis in routine care. <h3>Method</h3> We analysed the Scottish HCV Database to identify patients with a liver stiffness measurement (LSM) ≥9.5 kPa, starting a Sof based regimen in Glasgow treatment centres between June and October 2014 inclusive. Data were obtained on demographics, LSM, cirrhosis status, treatment status, baseline labs, Child’s score, drug and alcohol use. Data were compared with trial inclusion/exclusion criteria. Baseline viral load, week 4 PCR, EOTR, SVR12 and premature discontinuations were recorded. <h3>Results</h3> 123 patients, were treated with either Sof/IFN/Rib (n = 108) or Sof/Rib (n = 15). Baseline characteristics are summarised in Table 1. 97 (78.9%) patients were cirrhotic (median LSM 20.8 (IQR 14.8–35.5)). The majority were GT3 (68, 55.3%) or GT1 (47, 38.2%). Half (61, 49.6%) were TE, including 9 PI failures. 65 (52.8%) would have failed at least one trial inclusion/exclusion criteria (37 (30.1%) due to baseline labs, 30 (24.4%) recent drug/ alcohol misuse, schizophrenia (1, (0.8%)). At week 4 38/121 (31.4%) patients were undetectable (RealTime HCV, Abbott), 49 (40.5%) detectable &lt;12 IU/ml, and 32 (26.4%) quantifiable (median 23 IU/ml, IQR 15–56). On an ITT basis, 103/114 (90.3%) patients achieved EOTR. 5 discontinued prematurely (including one due to an AE and one death unrelated to treatment), 5 were lost to follow up. 1 patient was detectable (&lt;12 iu/ml) at end of treatment. Per protocol 37/44 (84%) of patients have to date achieved an SVR12. SVR data for the remaining cohort will be presented. <h3>Conclusion</h3> Patients with advanced fibrosis/cirrhosis and unfavourable baseline characteristics can be treated effectively with Sofosbuvir based regimens. High rates of detectable HCV RNA at week 4, did not appear to impact on end of treatment response. Initial SVR12 results are encouraging. <h3>Disclosure of interest</h3> D. Sutherland: None Declared, E. Forrest: None Declared, M. Heydtmann: None Declared, M. Priest: None Declared, P. Mills: None Declared, J. Morris: None Declared, A. Stanley: None Declared, R. Fox Consultant for: Gilead, Janssen, BMS, Abbvie, Speaker Bureau of: Gilead, Janssen, BMS, Abbvie, S. Barclay Consultant for: Gilead, Janssen, BMS, Abbvie, Speaker Bureau of: Gilead, Janssen.
SAT0277 Clinical, Ultrasound and Radiographic Evaluation of the Hip Joints in Ankylosing Spondylitis Patients with Active Disease: Table 1.
Authors: F. Wink, F. Maas, G. Bruyn, E. van der Veer, H. Bootsma, E. Brouwer, S. Arends, A. Spoorenberg
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Hip involvement is a characteristic extra-spinal manifestation of ankylosing spondylitis (AS). Inflammation of the hip joints may lead to structural damage. Hip involvement in AS is associated with more severe disease and functional impairment. <h3>Objectives</h3> To assess the prevalence of hip involvement in AS patients with active disease. Furthermore, to investigate the mutual associations between the different assessments used to evaluate hip involvement. <h3>Methods</h3> Between November 2004 en October 2008, consecutive outpatients from the Groningen Leeuwarden AS (GLAS) cohort before starting with Tumor Necrosis Factor (TNF)-α blocking therapy with radiographs of the pelvis and available Power Doppler Ultrasound (PDUS) examination of the hip joints were included. All patients fulfilled the modified New York criteria for AS. Patients history of hip involvement was assessed (yes /no) and the following assessments were evaluated in bilateral hip joints separately: tender hip joint assessed with physical examination (yes/no), PDUS examination for inflammatory (yes/no) and structural lesions (yes/no) and the Bath Ankylosing Spondylitis Radiology Index (BASRI-hip 0-4) to assess radiographic hip involvement. This was defined as BASRI-hip score ≥2. To investigate the mutual associations between these assessments Chi-square, Phi coefficients and percentage concordance were calculated. <h3>Results</h3> Mean age of the 111 included AS patients was 43 years (SD ±10.9), median symptom duration was 15 years (range 2-49), 71% was male and 81% was HLA-B27 positive. History of hip involvement was present in 22 (20%) patients. Twenty-five (23%) patients had ≥1 tender hip joint. PDUS examination showed inflammatory lesions in 19 (17%) patients and structural lesions in 22 (20%) patients. Radiographic damage of at least one hip joint was seen in 11 (10%) patients. A strong correlation was found between history of hip involvement and BASRI-hip total score ≥2 (Table 1). In all 222 hip joints evaluated moderate correlations were found between BASRI-hip score ≥2 and structural PDUS lesions and between structural PDUS lesions and tender hip joints. As to the other assessments of hip involvement no significant correlations were found (Table 1). The concordance rates were relatively high due to overall few hip abnormalities (Table 1). <h3>Conclusions</h3> In this cohort study the prevalence of hip involvement in AS patients with active disease ranged between 10% and 23% depending on which assessment used. The strongest correlation was found between radiographic hip joint damage and the history of hip involvement. Surprisingly, no association was found between tender hip joints assessed with physical examination and the inflammatory PDUS lesions. <h3>Disclosure of Interest</h3> None declared
Magnetic resonance imaging of the posterior fossa in autistic adults
Authors: H J Garber, E R Ritvo
Journal: American Journal of Psychiatry (1992)

Magnetic resonance imaging measurements were obtained for 12 adults with DSM-III-defined autism and a matched group of 12 normal subjects. No significant differences were found for mean midsagittal areas of pons, fourth ventricle, cerebellar vermis, or vermis lobules. No significant brain abnormalities were observed in either group.
IMMIGRATION AND PUBLIC HEALTH.
Authors: A J McLaughlin
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical features of cocaine-induced paranoia
Authors: S L Satel, S M Southwick, F H Gawin
Journal: American Journal of Psychiatry (1991)

The authors' objective was to assess the frequency and nature of cocaine-induced paranoia.They interviewed 50 cocaine-dependent men consecutively admitted to a 28-day rehabilitation program.Thirty-four (68%) of the 50 men reported highly distressing transient paranoid states in the context of cocaine use. The men who experienced paranoia did not differ from those who did not in age, race, or measures of cocaine use. The mean duration and amount of cocaine use before development of paranoia of the men who reported paranoia were not significantly different from the mean lifetime duration and amount of cocaine used by the men who did not report paranoia. Paranoia became more severe and developed more rapidly with continued cocaine use.The transient paranoid state appears to be a common feature of cocaine dependence and does not seem to be simply a result of exceeding a threshold of use. Rather, affected individuals might possess a predisposition to this drug-induced state. The fact that paranoia became more severe and developed more rapidly with continued drug use is consistent with a sensitization model of cocaine-induced paranoia. In vulnerable individuals, limbic sensitization may underlie its expression, but localization to a specific brain region is speculative. Quantity of use and route of administration do not appear directly to predispose to this phenomenon. Future investigations must be aimed at uncovering the markers and meaning of vulnerability to transient paranoia in heavy cocaine users.
Randomized, double-blind, crossover, placebo-controlled comparison of propranolol and betaxolol in the treatment of neuroleptic-induced akathisia
Authors: J P Dumon, J Catteau, F Lanvin, B A Dupuis
Journal: American Journal of Psychiatry (1992)

Beta-blocking agents, particularly propranolol, are considered effective in the treatment of neuroleptic-induced akathisia, but considerable controversy exists about the involved receptor subtype(s). The authors conducted a randomized, controlled trial comparing the effects of propranolol and betaxolol to determine whether central beta 1-adrenoceptor blockade is sufficient to correct neuroleptic-induced akathisia.The subjects were 19 patients whose neuroleptic-induced akathisia responded to 20 mg/day of propranolol and subsequently reemerged during a placebo washout period. They were randomly assigned to propranolol (20 or 40 mg/day) or betaxolol (10 or 20 mg/day) and, after another placebo period, were switched to the second beta blocker.There was no significant difference in the antiakathisia effects of propranolol and betaxolol.The lack of difference between propranolol and betaxolol suggests that beta 1-adrenoceptor blockade is sufficient to improve neuroleptic-induced akathisia. The results of this explanatory study need therapeutic confirmation.
Nutritional status of advanced lung cancer patients and its effect on survival
Authors: N. Swinton, G. Kasymjanova, H. Kreisman, D. Small, K. Gray-Donald, N. MacDonald
Journal: Journal of Clinical Oncology (2008)

9567 Background: Weight loss and malnutrition are common in patients with non-small cell lung cancer (NSCLC) and have a negative impact on survival. Early detection and intervention may impact positively on quality of life. The Patient Generated Subjective Global Assessment (PG-SGA) is a validated tool for screening nutritional status and triaging cancer patients with a potential score of 36 (Ottery, 2000). Methods: We measured the need for nutritional intervention in 118 newly diagnosed advanced NSCLC outpatients (stages 3B/4) using the PG-SGA score prior to any treatment. Patients were triaged into 4 Nutritional Triage (NT) groups based on Ottery’s recommendations: scores of 0–1 (NT I) required no intervention, 2–3 (NT II) required education, 4–8 (NT III) required intervention by a dietitian and 9 or greater (NT IV) were in critical need of nutritional intervention. We investigated the association between NT groups and weight loss, survival, inflammatory markers (CRP), LDH and albumin. Results: 118 recently diagnosed outpatients (M 63, F 55) aged 64 ± 11.3 years were studied. Patients were triaged into NT I - 21 (18percnt;) pts, NT II - 13 (11percnt;) pts, NT III - 34 (29percnt;) pts and NT IV - 50 (42percnt;) pts. Median PG-SGA score was 7. 76percnt; of pts had 0–5percnt; weight loss in the past month, 10percnt; had a weight loss of 5–10percnt; and 14percnt; had a weight loss >10percnt;. Low albumin, high LDH and high CRP were significantly associated with a higher PG-SGA score (p=0.016, 0.029 and 0.022 respectively). The NT group was significantly associated with survival. Overall median survival was 7.0 months. The median (95percnt; CI) survival of patients in NT groups I, II, III and IV was 12 (CI: 9–16), 10 (CI: 7–13), 8 (CI: 6–10), 4 (CI: 2–6) months respectively, p<0.0001.The amount of weight loss was also significantly associated with survival. Those with <5percnt; weight loss had a survival of 8 (CI: 5–10) mo vs. 5 (CI: 2–9) mo in those with weight loss ≥5percnt;. Conclusions: The need for nutritional intervention in advanced lung cancer patients is very high. There was a significant association between the PG-SGA NT groups and survival. Weight loss alone may not identify patients in need of nutritional intervention. However the weight loss was still discriminatory with respect to survival. The PG-SGA is a simple screening tool for triaging the nutritional needs of patients with advanced lung cancer. No significant financial relationships to disclose.
AB0618 Effect of Age at Onset on Disease Activity and Clinical Features in Patients with Primary Sjögren's Syndrome
Authors: S. Nishiyama, T. Aita, Y. Yoshinaga, S. Miyawaki
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Primary Sjögren9s syndrome (pSS) is an autoimmune disease characterized by lymphocyte infiltration in exocrine glands. Although most of the patients developed the disease in middle age, there are younger onset patients. <h3>Objectives</h3> To examine relationship between age at onset and clinical features including disease activity in patients with pSS. <h3>Methods</h3> Clinical data of 75 women with pSS who visited our hospital from Aug. 2010 to Dec. 2014 were collected from medical charts. Of them, ESSPRI<sup>1</sup> and ESSDAI<sup>2</sup> were assessed in 72 and 71 patients, respectively. <h3>Results</h3> Average age, age at onset, and duration of disease were 60.9±12.6, 48.3±13.9, and 12.8±7.3 years, respectively. Number of patients with low (ESSDAI &lt;5), moderate (ESSDAI 5 ∼ 13), and high disease activity (ESSDAI 14) were 45, 20, and 6, receptivity. Corticosteroid was used in 60.8% of patients. Average dose of steroid (equivalent dose of prednisolone) was 3.1±2.1 mg/day, and that of high disease activity group (6.3±4.4mg/day) was significantly higher than that of moderate (1.6±1.4 mg/day) or low disease activity group (1.6±1.6mg/day). Patients with younger onset (under 40) had significantly high score of ESSDAI (7.8±5.9) compared with middle age or elderly onset patients (3.7±4.3), and there was a marked difference in its domain of lymphadenopathy between younger onset and middle age or elderly onset patients. There was no difference of ESSPRI between them (5.1±2.1 vs. 4.3±2.1); however, its item of fatigue score was significantly higher in younger onset group than in middle age or elderly onset group (5.9±2.9 vs. 4.3±2.9). Positive rate of anti-Ro/SSA and anti-La/SSB antibody in younger onset group was 100% and 36.8%, respectively and it did not differ from that in middle or elderly onset group (89.3% and 33.9%, respectively). <h3>Conclusions</h3> Younger onset pSS patients had higher disease activity than middle age or elderly onset patients. Severity of fatigue and lymphadenopathy were the clinical characteristics in younger onset pSS. <h3>References</h3> Seror R, et al. Ann Rheum Dis 2011; 70:968-72. doi: 10.1136/ard.2010.143743 Seror R, et al. Ann Rheum Dis 2010;69:1103-9. doi: 10.1136/ard.2009.110619 <h3>Disclosure of Interest</h3> None declared
SP0044 Automated Laboratory Analysis? Men Against Machines
Authors: E. Feist
Journal: Annals of the Rheumatic Diseases (2015)

The detection of autoantibodies is an important and sophisticated step in the diagnosis of several systemic autoimmune diseases. Due to numerous known auto-antigens as well as to time consuming procedures, automates are increasingly used for detection of antibodies in solid phase but also immunofluorescence (IIF) based assays. Especially for the detection of anti-nuclear antibodies (ANA) and anti-neutrophil cytoplasmatic antibodies (ANCA), different methods are available all bearing their own advantages and limitations. To overcome subjectivity of IIF and for discrimination between positive and negative samples, automated digital reading systems have been developed during the last years. In addition, high throughput solid phase immunoassays using well characterized antigens are increasingly used. However, despite all the advances in the field of automated antibody detection, many concerns exist and challenges remain unsolved. This presentation will focus on the current status of automated autoantibody detection including IIF reading systems, the level of accuracy of these systems in pattern recognition and the correlation between the results provided by the instruments compared to manual testing. <h3>Disclosure of Interest</h3> E. Feist Grant/research support from: Aesku, Orgentec, Medipan, Consultant for: Aesku, Orgentec, Medipan
In defense of community mental health
Authors: J Zusman, H R Lamb
Journal: American Journal of Psychiatry (1977)

Initial enthusiasm for community mental health has given way to a barrage of criticism, musch of it deserved. Originated to deal with abysmal conditions in state hospitals, community mental health focused instead on primary prevention, political activism, and the mildly mentally ill. The authors propose a return to the original fundamentals, stressing that the highest priority be given to community treatment and rehabilitation of the severely mentally ill.
Congenital Long-QT Syndrome
Authors: J Benhorin, A Medina
Journal: New England Journal of Medicine (1997)

Figure 1. A 25-year-old woman who had had a single syncopal episode two years earlier was hospitalized after a two-minute episode of syncope during an argument with a police officer over a traffic ticket. A 12-lead electrocardiogram obtained on admission showed sinus rhythm, 52 beats per minute, with a markedly prolonged QT interval of 0.68 second. Twenty-four-hour Holter monitoring in the hospital revealed recurrent asymptomatic, mostly short, episodes of torsade de pointes. One such episode occurred during sleep and degenerated into ventricular fibrillation that lasted 11/2 minutes and terminated spontaneously. At that time, the patient wrote in her diary that . . .
Organic Radioiodo Compounds for Cancer Research&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;&lt;xref ref-type="fn" rid="fn2"&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/xref&gt;
Authors: H S BLOCH, F E RAY
Journal: JNCI Journal of the National Cancer Institute (1946)

Organic Radioiodo Compounds for Cancer Research Henry S. Bloch, Henry S. Bloch John Eisman Fellow 1944–46 Gastric Research Laboratory, Cincinnati General Hospital, and the Department of Chemistry, University of Cincinnati4 Search for other works by this author on: Oxford Academic PubMed Google Scholar Francis Earl Ray Francis Earl Ray Gastric Research Laboratory, Cincinnati General Hospital, and the Department of Chemistry, University of Cincinnati4 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 7, Issue 2, October 1946, Pages 61–66, https://doi.org/10.1093/jnci/7.2.61 Published: 01 October 1946 Article history Received: 01 July 1946 Published: 01 October 1946
Acute and Chronic Renal and Hepatic Disease in Rats Fed Mirex
Authors: Melvin D. Reuber
Journal: JNCI Journal of the National Cancer Institute (1977)

Journal Article Acute and Chronic Renal and Hepatic Disease in Rats Fed Mirex Get access Melvin D. Reuber, M.D. Melvin D. Reuber, M.D. 11014 Swansfield Road Columbia, Maryland 21044 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 59, Issue 4, October 1977, Pages 1051–1052, https://doi.org/10.1093/jnci/59.4.1051 Published: 01 October 1977